<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-id journal-id-type="pmc-domain-id">3848</journal-id><journal-id journal-id-type="pmc-domain">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title-group><journal-title>bioRxiv</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn><publisher><publisher-name>Cold Spring Harbor Laboratory Preprints</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12154943</article-id><article-id pub-id-type="pmcid-ver">PMC12154943.1</article-id><article-id pub-id-type="pmcaid">12154943</article-id><article-id pub-id-type="pmcaiid">12154943</article-id><article-id pub-id-type="pmid">40502015</article-id><article-id pub-id-type="doi">10.1101/2025.05.28.656658</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Kinetic Modeling of Covalent Inhibition: Effects of Rapidly Fluctuating Intermediate States</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ghaby</surname><given-names initials="K">Kyle</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5254-2712</contrib-id><name name-style="western"><surname>Roux</surname><given-names initials="B">Beno&#238;t</given-names></name></contrib><aff id="A1">Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago, IL 60637</aff></contrib-group><author-notes><corresp id="CR1"><email>roux@uchicago.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>5</month><year>2025</year></pub-date><issue-id pub-id-type="pmc-issue-id">490398</issue-id><elocation-id>2025.05.28.656658</elocation-id><pub-history><event event-type="pmc-release"><date><day>11</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>12</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-24 13:25:29.623"><day>24</day><month>06</month><year>2025</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</ext-link>, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihpp-2025.05.28.656658v1.pdf"/><self-uri content-type="pdf">nihpp-2025.05.28.656658.pdf</self-uri><abstract id="ABS1"><p id="P1">There is increasing interest in the discovery of small-molecule inhibitors that form covalent bonds with their targets for therapeutic applications. Nevertheless, identifying clear rational design principles remains challenging because the action of these molecules cannot be understood as common noncovalent inhibitors. Conventional kinetic models often reduce the binding of covalent inhibitors to a two-step irreversible process, overlooking rapid complex dynamics of the associated unlinked inhibitor before the formation of the covalent bond with its target. In the present analysis, we expand the intermediate state into two conformations&#8212;reactive (E.I) and nonreactive (E..I). To illustrate the consequences of such simplification, the expanded kinetic model can be reduced to an effective two-step scheme expressed in terms of the equilibrium probability of the unlinked inhibitor to form either conformation. A mass-action-based numerical workflow is implemented to simulate time-dependent kinetics, overcoming the common limitations of empirical models. The numerical workflow helps relate microscopic states observed in molecular dynamics simulations to macroscopic observables like <inline-formula><mml:math id="M1" display="inline"><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and the apparent rate of covalent inhibition, showing the impact of transient intermediates on dissociation rates and potency. The proposed framework refines the interpretation of dose-response data, aiding medicinal chemists in optimizing covalent inhibitors and provides a quantitative platform for relating molecular conformational distributions to empirical parameters.</p></abstract><abstract id="ABS2" abstract-type="graphical"><title>Graphical Abstract</title><p id="P2">
<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="nihpp-2025.05.28.656658v1-f0001.jpg"/>
</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S1"><title>Introduction</title><p id="P3">For a long time, inhibitory small-molecules that form covalent bonds with their targets, <italic toggle="yes">i.e</italic>. covalent inhibitors, were largely eschewed in drug development due to concerns over off-target effects, assay and delivery interference, and metabolitic toxicity.<sup><xref rid="R1" ref-type="bibr">1</xref>&#8211;<xref rid="R8" ref-type="bibr">8</xref></sup> With the improvements in drug design and optimization over the past couple decades, targeted covalent inhibition is becoming a promising and widely recognized strategy for exceeding the potency and selectivity of noncovalent inhibition.<sup><xref rid="R9" ref-type="bibr">9</xref>&#8211;<xref rid="R26" ref-type="bibr">26</xref></sup> These enhancements should lead to improvements in the translation of <italic toggle="yes">in vitro</italic> to <italic toggle="yes">in vivo</italic> efficacy and safety profile.<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup> Covalent inhibitors are also useful as probes for chemoproteomic applications.<sup><xref rid="R29" ref-type="bibr">29</xref></sup></p><p id="P4">Nevertheless, the rational design of covalent inhibitors remains extremely challenging. Today&#8217;s dominant strategy to design a covalent inhibitor is to start from a molecular scaffold that displays some reversible binding affinity to a protein of interest and attach to it a reactive functional group or &#8220;warhead&#8221; that targets a specific residue in the binding site.<sup><xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R30" ref-type="bibr">30</xref>&#8211;<xref rid="R38" ref-type="bibr">38</xref></sup> Conventional docking methods developed to deal with noncovalent protein&#8211;ligand interactions have been adapted to model the binding of a covalent ligand with the protein.<sup><xref rid="R39" ref-type="bibr">39</xref>&#8211;<xref rid="R45" ref-type="bibr">45</xref></sup> It is commonly assumed that poses with the warhead in close proximity to the target residue can be used to predict a covalently-bound adduct, and computational workflows based on these ideas have been proposed.<sup><xref rid="R34" ref-type="bibr">34</xref>&#8211;<xref rid="R36" ref-type="bibr">36</xref>,<xref rid="R46" ref-type="bibr">46</xref>&#8211;<xref rid="R50" ref-type="bibr">50</xref></sup> Nevertheless, there is a wide range of issues. In particular, conventional docking often falls short when a protein target is flexible and can adopt multiple distinct conformations. It is also worth emphasizing that the mere presence of a reactive residue near a ligand binding site is not sufficient to guarantee a successful covalent strategy; the local chemical environment of the target residue must be carefully considered to determine the suitability of this approach.<sup><xref rid="R51" ref-type="bibr">51</xref></sup> Dynamics before the covalent bond is formed is also thought to play a key role.<sup><xref rid="R52" ref-type="bibr">52</xref>,<xref rid="R53" ref-type="bibr">53</xref></sup> Covalent inhibition ultimately depends on a chemical reaction taking place in the confined environment of a protein binding pocket. Residues near the warhead, in turn, may act as catalysts or steric obstacles at various steps along the reaction pathway. The situation is very different than for a reaction occurring in bulk solution. Despite their short lifetime, the rapidly fluctuating intermediate conformational states at play in all of these issues have a profound and complex impact on the apparent reaction rate.</p><p id="P5">The purpose of kinetic models, in the context of a drug development project, is to help draw accurate lessons from experimental observations in order to make judicious decisions to orient the design strategy in a productive direction. Due to the limited resolution, kinetic measurements of covalent inhibition have commonly been interpreted in terms a simple two-step mechanism.<sup><xref rid="R54" ref-type="bibr">54</xref>&#8211;<xref rid="R56" ref-type="bibr">56</xref></sup> The simple picture is that the inhibitor initially diffuses in the bulk solution to encounter the kinase enzyme and associate with the active site, followed by the irreversible inactivation of the enzyme due to the formation of the covalent adduct. A critical issue with such a minimal two-step model is that it may obscure important microscopic factors that are at play, which in turn may misdirect the design strategy. For example, kinetic data interpreted in light of the two-step model tend to ascribe the apparent rate of inactivation to the final chemical step that leads to the formation of the covalent linkage. Thus, while a slow inactivation rate constant may be caused by a low probability of a reaction-ready pose by the unlinked ligand occupying the binding site, the observation of an apparent slow rate might erroneously be attributed to the poor reactivity of the warhead, thereby leading the design strategy in a wrong direction.</p><p id="P6">While the mathematical simplicity of a model is an important advantage to analyze experimental data, it should not be a determining factor. Computational methods for numerically predicting molecular behavior and solving complex kinetic schemes have grown much more accessible and reliable. The precision of analysis depends on the precision of the kinetic scheme. Also of interest, the fluctuations predicted by classical molecular dynamics (MD) simulations based on atomic models can provide quantitative information that can be incorporated into a kinetic scheme to affect the observable covalent occupancy. A recent computational study of the irreversible covalent inhibitor of Bruton&#8217;s tyrosine kinase (BTK) ibrutinib illustrates these ideas.<sup><xref rid="R52" ref-type="bibr">52</xref></sup> Classical MD simulations of the unlinked compound associated with the kinase binding pocket showed that only a small fraction (less than 3%) of the configurations were reaction-ready despite the fact that the inhibitor remains very close to the crystallographic binding pose. Quantitative agreement with experimental data was achieved only once this information was combined with the result of hybrid QM/MM calculation of the covalent reaction. The kinetic effects of rapidly fluctuating intermediate conformational states have been characterized and discussed in other fields,<sup><xref rid="R57" ref-type="bibr">57</xref>&#8211;<xref rid="R59" ref-type="bibr">59</xref></sup> but has not been extensively considered in covalent inhibition.</p><p id="P7">Owing to their growing significance, it is important to develop more accurate and more realistic mathematical models of covalent inhibitors.<sup><xref rid="R60" ref-type="bibr">60</xref>&#8211;<xref rid="R68" ref-type="bibr">68</xref></sup> It is the central goal of the present work to help clarify the impact of rapid conformational fluctuations on the apparent potency of covalent inhibitors, which should hopefully lead to more effective design strategies.</p></sec><sec id="S2"><title>Theoretical Framework</title><sec id="S3"><title>Kinetic schemes</title><p id="P8">At the simplest level, the kinetics of irreversible covalent inhibition are often described as a two-step mechanism shown in <xref rid="FD1" ref-type="disp-formula">Scheme 1</xref>,<sup><xref rid="R54" ref-type="bibr">54</xref>&#8211;<xref rid="R56" ref-type="bibr">56</xref></sup>
<disp-formula id="FD1"><label>Scheme 1</label><mml:math id="M41" display="block"><mml:mtext>E</mml:mtext><mml:mo>+</mml:mo><mml:mtext>I</mml:mtext><mml:munder><mml:mrow><mml:mover><mml:mrow><mml:mo>&#8652;</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:mrow></mml:munder><mml:mtext>E</mml:mtext><mml:mo>&#183;</mml:mo><mml:mo>&#183;</mml:mo><mml:mo>&#183;</mml:mo><mml:mtext>I</mml:mtext><mml:mover><mml:mrow><mml:mo>&#8594;</mml:mo></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:mrow></mml:mover><mml:mtext>E</mml:mtext><mml:mo>-</mml:mo><mml:mtext>I</mml:mtext></mml:math></disp-formula>
where <inline-formula><mml:math id="M42" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> is the bimolecular association rate, <inline-formula><mml:math id="M43" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> is the apparent dissociate rate, and <inline-formula><mml:math id="M44" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> is the apparent inactivation rate constant. Initially, the inhibitor (I) diffuses in the bulk solution to encounter the kinase enzyme (E) and associate with the active site, resulting in the reversible noncovalent complex (E&#8943;I). The final step describes the inactivation of the enzyme as an irreversible process that results in the covalent adduct (E-I). Intermediates such as noncovalent fluctuations and the quantum-mechanical mechanisms of bond formation are combined in E&#8230;I and accounted for in <inline-formula><mml:math id="M45" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="M46" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula>. We explicitly attach the label &#8216;app&#8221; to these rates because they implicitly subsume additional processes, as will be clarified in the following.</p><p id="P9"><xref rid="FD2" ref-type="disp-formula">Scheme 2</xref> splits the state E&#8943;I into nonreactive (E..I) and reactive (E.I) intermediate states, where the reactive intermediate state meets some distance and orientation requirements necessary for the progress of the covalent reaction between the warhead and the target residue. For the sake of simplicity, it is assumed that only the nonreactive state can dissociate.
<disp-formula id="FD2"><label>Scheme 2</label><mml:math id="M47" display="block"><mml:mi mathvariant="normal">E</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:munder><mml:mrow><mml:mover><mml:mrow><mml:mo>&#8652;</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:mi mathvariant="normal">E</mml:mi><mml:mo>&#183;</mml:mo><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:munder><mml:mrow><mml:mover><mml:mrow><mml:mo>&#8652;</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>r</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>nr</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:mi mathvariant="normal">E</mml:mi><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mover><mml:mrow><mml:mo>&#8594;</mml:mo></mml:mrow><mml:mrow><mml:mpadded><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mpadded></mml:mrow></mml:mover><mml:mi mathvariant="normal">E</mml:mi><mml:mo>-</mml:mo><mml:mi mathvariant="normal">I</mml:mi></mml:math></disp-formula>
The equilibrium probability of the unlinked inhibitor to form the either reactive <inline-formula><mml:math id="M48" display="inline"><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:math></inline-formula> or nonreactive complex <inline-formula><mml:math id="M49" display="inline"><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mtext>nr</mml:mtext></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:math></inline-formula> can be defined from the species concentrations as,
<disp-formula id="FD3"><label>(1)</label><mml:math id="M50" display="block"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>&#8801;</mml:mo><mml:mfrac><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mo>]</mml:mo><mml:mo>+</mml:mo><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mo>&#183;</mml:mo><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mfrac></mml:math></disp-formula>
<disp-formula id="FD4"><label>(2)</label><mml:math id="M51" display="block"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mtext>nr</mml:mtext></mml:mrow></mml:msub><mml:mo>&#8801;</mml:mo><mml:mfrac><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mo>&#183;</mml:mo><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mo>]</mml:mo><mml:mo>+</mml:mo><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mo>&#183;</mml:mo><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mo>]</mml:mo></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></disp-formula>
Classical MD simulations indicate that the fluctuations of the unlinked inhibitor between the reactive and nonreactive pose may take place on a timescale of microseconds.<sup><xref rid="R52" ref-type="bibr">52</xref></sup> This is significantly faster than the other transitions, whose rate constants are typically on the order of minutes or even hours. Since these states are rapidly equilibrated relative to the rest of the scheme,
<disp-formula id="FD5"><label>(3)</label><mml:math id="M52" display="block"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>&#8776;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>nr</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula>
<disp-formula id="FD6"><label>(4)</label><mml:math id="M53" display="block"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mtext>nr</mml:mtext></mml:mrow></mml:msub><mml:mo>&#8776;</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>nr</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>nr</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula>
and <xref rid="FD2" ref-type="disp-formula">Scheme 2</xref> can be reduced and made equivalent to a two-step system, as shown in <xref rid="FD7" ref-type="disp-formula">Scheme 3</xref>,
<disp-formula id="FD7"><label>Scheme 3</label><mml:math id="M54" display="block"><mml:mrow><mml:mtext>E</mml:mtext><mml:mo>+</mml:mo><mml:mtext>I</mml:mtext><mml:munderover><mml:mo>&#8652;</mml:mo><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mtext>nr</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:munderover><mml:mtext>E</mml:mtext><mml:mo>&#8943;</mml:mo><mml:mtext>I</mml:mtext><mml:mover><mml:mo>&#8594;</mml:mo><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi mathvariant="normal">r</mml:mi></mml:msub><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mover><mml:mtext>E</mml:mtext><mml:mo>&#8722;</mml:mo><mml:mtext>I</mml:mtext></mml:mrow></mml:math></disp-formula>
where the apparent dissociation rate constant <inline-formula><mml:math id="M55" display="inline"><mml:mo>(</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:math></inline-formula> equals <inline-formula><mml:math id="M56" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mtext>nr</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula>, and the apparent inactivation rate constant <inline-formula><mml:math id="M57" display="inline"><mml:mo>(</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:math></inline-formula> equals <inline-formula><mml:math id="M58" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula>. This equivalence was verified with numerical simulations, <italic toggle="yes">i.e</italic>., for the cases examined in the present study, the results obtained by solving the ODEs numerically for <xref rid="FD2" ref-type="disp-formula">Scheme 2</xref> or from <xref rid="FD7" ref-type="disp-formula">Scheme 3</xref> were identical. To highlight the effects of <inline-formula><mml:math id="M59" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> in the absence of the irreversible covalent step from <xref rid="FD2" ref-type="disp-formula">Scheme 2</xref>, it is also of interest to consider a non-covalent version as <xref rid="FD8" ref-type="disp-formula">Scheme 4</xref>,
<disp-formula id="FD8"><label>Scheme 4</label><mml:math id="M60" display="block"><mml:mi mathvariant="normal">E</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:munder><mml:mrow><mml:mover><mml:mrow><mml:mo>&#8652;</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:mi mathvariant="normal">E</mml:mi><mml:mo>&#183;</mml:mo><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:munder><mml:mrow><mml:mover><mml:mrow><mml:mo>&#8652;</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>nr</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:mi mathvariant="normal">E</mml:mi><mml:mo>&#183;</mml:mo><mml:mi mathvariant="normal">I</mml:mi></mml:math></disp-formula>
which is also useful for illustrating the influence of rapid intermediates on the residence time <inline-formula><mml:math id="M61" display="inline"><mml:mo>(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> of a bound ligand.</p></sec><sec id="S4"><title>Simulation methodology</title><p id="P10">The time course of species concentrations in a well-defined (<italic toggle="yes">i.e</italic>. the rate constants and stoichiometry are known or parametric for each transition), Markovian kinetic scheme can be solved deterministically by integrating a set of ordinary differential equations (ODEs) for concentration with respect to time.<sup><xref rid="R69" ref-type="bibr">69</xref></sup> These ODEs are derived from the law of mass action and formulated based on the stoichiometric coefficients and rate constants of each transition in the scheme. This fast, flexible, and straightforward framework adequately models the <italic toggle="yes">in vitro</italic> kinetics<sup><xref rid="R70" ref-type="bibr">70</xref></sup> of covalent inhibition.</p><p id="P11">Let <inline-formula><mml:math id="M62" display="inline"><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> represent the concentration of species <inline-formula><mml:math id="M63" display="inline"><mml:mi>S</mml:mi></mml:math></inline-formula> at time <inline-formula><mml:math id="M64" display="inline"><mml:mi>t</mml:mi></mml:math></inline-formula>. The time derivative <inline-formula><mml:math id="M65" display="inline"><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:math></inline-formula> is given by the sum of contributions from all transitions involving species <inline-formula><mml:math id="M66" display="inline"><mml:mi>S</mml:mi></mml:math></inline-formula>,
<disp-formula id="FD9"><label>(5)</label><mml:math id="M67" display="block"><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mtext mathvariant="italic">dt</mml:mtext></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:munder><mml:mo>&#8721;</mml:mo><mml:mi>T</mml:mi></mml:munder><mml:mfenced><mml:mrow><mml:mi>&#916;</mml:mi><mml:msub><mml:mi>&#957;</mml:mi><mml:mi>S</mml:mi></mml:msub><mml:mspace width="0.5em"/><mml:msub><mml:mi>k</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:munder><mml:mo>&#8719;</mml:mo><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mo>&#8242;</mml:mo></mml:msup><mml:mo>&#8712;</mml:mo><mml:mtext>Src</mml:mtext><mml:mfenced><mml:mi>T</mml:mi></mml:mfenced></mml:mrow></mml:munder><mml:msubsup><mml:mi>C</mml:mi><mml:msup><mml:mi>S</mml:mi><mml:mo>&#8242;</mml:mo></mml:msup><mml:mrow><mml:msub><mml:mi>&#957;</mml:mi><mml:mrow><mml:msup><mml:mi>S</mml:mi><mml:mo>&#8242;</mml:mo></mml:msup><mml:mo>,</mml:mo><mml:mtext>Src</mml:mtext><mml:mfenced><mml:mi>T</mml:mi></mml:mfenced></mml:mrow></mml:msub></mml:mrow></mml:msubsup></mml:mrow></mml:mfenced></mml:math></disp-formula>
where <inline-formula><mml:math id="M68" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the rate constant of transition <inline-formula><mml:math id="M69" display="inline"><mml:mi>T</mml:mi></mml:math></inline-formula>, and <inline-formula><mml:math id="M70" display="inline"><mml:mi>&#916;</mml:mi><mml:msub><mml:mrow><mml:mi>&#957;</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is the difference between the stoichiometric coefficients of species <inline-formula><mml:math id="M71" display="inline"><mml:mi>S</mml:mi></mml:math></inline-formula> as a target and as a source in transition <inline-formula><mml:math id="M72" display="inline"><mml:mi>T</mml:mi></mml:math></inline-formula> (<italic toggle="yes">i.e</italic>. <inline-formula><mml:math id="M73" display="inline"><mml:mfenced open="" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>&#957;</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:mtext>Tgt</mml:mtext><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>&#957;</mml:mi></mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mo>,</mml:mo><mml:mtext>Src</mml:mtext><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math></inline-formula>.</p><p id="P12">A system of these rate laws with any degree of (non)linearity can be expressed and solved in matrix notation as,
<disp-formula id="FD10"><label>(6)</label><mml:math id="M74" display="block"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:mover accent="true"><mml:mi>C</mml:mi><mml:mo>&#8594;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mtext mathvariant="italic">dt</mml:mtext></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>C</mml:mi><mml:mo>&#8594;</mml:mo></mml:mover><mml:mrow><mml:msub><mml:mtext>N</mml:mtext><mml:mrow><mml:mtext>Src</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>&#183;</mml:mo><mml:mtext>diag</mml:mtext><mml:mfenced><mml:mover accent="true"><mml:mi>k</mml:mi><mml:mo>&#8594;</mml:mo></mml:mover></mml:mfenced><mml:mo>&#183;</mml:mo><mml:mstyle><mml:mtext>N</mml:mtext></mml:mstyle></mml:mrow></mml:math></disp-formula>
The complete stoichiometry matrix, <inline-formula><mml:math id="M75" display="inline"><mml:mtext>N</mml:mtext></mml:math></inline-formula>, is the difference between the target and source stoichiometry matrices (<italic toggle="yes">i.e</italic>. <inline-formula><mml:math id="M76" display="inline"><mml:mtext>N</mml:mtext><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mtext>N</mml:mtext></mml:mrow><mml:mrow><mml:mtext>Tgt</mml:mtext></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mtext>N</mml:mtext></mml:mrow><mml:mrow><mml:mtext>Src</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula>). The stoichiometric matrices have <inline-formula><mml:math id="M77" display="inline"><mml:mi>m</mml:mi></mml:math></inline-formula> rows corresponding to the transitions and <inline-formula><mml:math id="M78" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> columns corresponding to the species. <inline-formula><mml:math id="M79" display="inline"><mml:mtext>diag</mml:mtext><mml:mo>(</mml:mo><mml:mover accent="true"><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mo>&#8594;</mml:mo></mml:mover><mml:mo>)</mml:mo></mml:math></inline-formula> is the diagonal matrix constructed from the vector of transition rate constants. The adjusted concentration vector, <inline-formula><mml:math id="M80" display="inline"><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mo>&#8594;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">N</mml:mi></mml:mrow><mml:mrow><mml:mtext>Src</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math></inline-formula>, is the column-wise (<italic toggle="yes">i.e</italic>. species-wise) product of the element-wise exponentiation of the concentration vector with the source stoichiometry matrix, <italic toggle="yes">i.e</italic>.,
<disp-formula id="FD11"><label>(7)</label><mml:math id="M81" display="block"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>C</mml:mi><mml:mo>&#8594;</mml:mo></mml:mover><mml:mrow><mml:msub><mml:mstyle><mml:mtext>N</mml:mtext></mml:mstyle><mml:mrow><mml:mtext>Src</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>&#8801;</mml:mo><mml:munder><mml:mstyle><mml:mo>&#8719;</mml:mo></mml:mstyle><mml:mi>n</mml:mi></mml:munder><mml:msub><mml:mrow><mml:mfenced close="]" open="["><mml:mrow><mml:msup><mml:mover accent="true"><mml:mi>C</mml:mi><mml:mo>&#8594;</mml:mo></mml:mover><mml:mrow><mml:msub><mml:mstyle><mml:mtext>N</mml:mtext></mml:mstyle><mml:mrow><mml:mtext>Src</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula>
<xref rid="FD10" ref-type="disp-formula">eq 6</xref> is numerically integrated over time with the scipy implementation of LSODA.<sup><xref rid="R71" ref-type="bibr">71</xref>&#8211;<xref rid="R73" ref-type="bibr">73</xref></sup> This vectorized rate function together with the rest of the infrastructure for modeling the schemes comprises GeKiM, an in-house and open-source Python package.</p><p id="P13">A Jupyter notebook to reproduce the simulations and plots herein is available on Github. The numerical values of the rate constants used in the simulations were chosen to reflect the regime commonly observed for covalent inhibitors, where <inline-formula><mml:math id="M82" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub><mml:mo>&#8810;</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:math></inline-formula><sup><xref rid="R74" ref-type="bibr">74</xref></sup></p></sec></sec><sec id="S5"><title>Results</title><sec id="S6"><title>Noncovalent vs covalent inhibition</title><p id="P14">Time courses of the total occupied populations of <xref rid="FD2" ref-type="disp-formula">Scheme 2</xref> and its noncovalent version <xref rid="FD8" ref-type="disp-formula">Scheme 4</xref> are compared in <xref rid="F1" ref-type="fig">Figure 1</xref> for various probabilities of a reactive conformation, <inline-formula><mml:math id="M83" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>. The purpose of <xref rid="FD8" ref-type="disp-formula">Scheme 4</xref> is to highlight the effects of <inline-formula><mml:math id="M84" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> in the absence of the irreversible covalent step from <xref rid="FD2" ref-type="disp-formula">Scheme 2</xref>. <inline-formula><mml:math id="M85" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> has a similar impact on the occupancy of both of the schemes. The noncovalent time courses demonstrate how <inline-formula><mml:math id="M86" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> can compensate for poor affinity and limit maximal occupancy. The irreversible covalent time courses demonstrate the dependence of covalent action rate on <inline-formula><mml:math id="M87" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>. Reversible covalent inhibition falls somewhere in between, depending on the ratio of covalent forward and backward rate constants.</p><p id="P15">As shown in <xref rid="F2" ref-type="fig">Figure 2</xref>, the propensity to adopt a conformation in which the ligand cannot dissociate significantly increases the lifetime of binding despite the short lifespan of the conformations themselves. The residence time derived from <xref rid="FD8" ref-type="disp-formula">Scheme 4</xref> can be expressed using the rapid-equilibrium approximation as,
<disp-formula id="FD12"><label>(8)</label><mml:math id="M88" display="block"><mml:mi>&#964;</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:math></disp-formula></p></sec><sec id="S7"><title>Effects on observable outcomes</title><sec id="S8"><title>Dose-rate analysis</title><p id="P16">The kinetics of covalent inhibitors are often studied in a pseudo-first order regime in the spirit of Michaelis-Menten kinetics,<sup><xref rid="R75" ref-type="bibr">75</xref>,<xref rid="R76" ref-type="bibr">76</xref></sup> with an excess of either inhibitor or enzyme. For the sake of convention, we will treat the inhibitor as the saturating species, so the biomolecular step can be linearly approximated as shown in <xref rid="FD13" ref-type="disp-formula">Scheme 5</xref>.
<disp-formula id="FD13"><label>Scheme 5</label><mml:math id="M89" display="block"><mml:mi mathvariant="normal">E</mml:mi><mml:munder><mml:mrow><mml:mover><mml:mrow><mml:mo>&#8652;</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mo>[</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mover></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:mrow></mml:munder><mml:mi mathvariant="normal">E</mml:mi><mml:mo>&#8943;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mover><mml:mrow><mml:mo>&#8594;</mml:mo></mml:mrow><mml:mrow><mml:mpadded><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:mrow></mml:mpadded></mml:mrow></mml:mover><mml:mi mathvariant="normal">E</mml:mi><mml:mo>-</mml:mo><mml:mi mathvariant="normal">I</mml:mi></mml:math></disp-formula>
In conventional experimental procedures of scoring an irreversible inhibitor&#8217;s on-target behavior,<sup><xref rid="R56" ref-type="bibr">56</xref></sup> the observed rate constant of covalent bond formation, <inline-formula><mml:math id="M90" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>obs</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula>, is first obtained by fitting the fractional population of the covalently-bound state (<italic toggle="yes">i.e</italic>. covalent occupancy&#8212;CO) to the pseudo-first order growth factor,
<disp-formula id="FD14"><label>(9)</label><mml:math id="M91" display="block"><mml:mtext>CO</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>&#8801;</mml:mo><mml:mfrac><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:mo>-</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mspace linebreak="newline"/><mml:mo>&#8776;</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>obs</mml:mtext></mml:mrow></mml:msub><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfenced></mml:math></disp-formula>
at various inhibitor concentrations. The variation of <inline-formula><mml:math id="M92" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>obs</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> as a function of initial inhibitor concentration, <inline-formula><mml:math id="M93" display="inline"><mml:mfenced open="[" close="" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math></inline-formula>, is then fitted to the Michaelis-Menten analog,
<disp-formula id="FD15"><label>(10)</label><mml:math id="M94" display="block"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>obs</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>[</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mo>[</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula>
The apparent rate constant of inactivation, <inline-formula><mml:math id="M95" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula>, is the maximal observed rate constant that occurs when the entire free enzyme population rapidly transitions into the reversible complex state. This limit is approached when <inline-formula><mml:math id="M96" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mo>[</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#8811;</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula>. The apparent inactivation constant, <inline-formula><mml:math id="M97" display="inline"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula>, is the concentration of the inhibitor that results in a half-maximal observed rate constant, and it can be expressed as,
<disp-formula id="FD16"><label>(11)</label><mml:math id="M98" display="block"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula>
A reaction may appear one-step in both non-saturating <inline-formula><mml:math id="M99" display="inline"><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mfenced open="" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math></inline-formula> and saturating <inline-formula><mml:math id="M100" display="inline"><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mfenced open="[" close="]" separators="|"><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#8811;</mml:mo><mml:mfenced open="" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math></inline-formula> conditions. These one-step approximations are distinguishable by the <inline-formula><mml:math id="M101" display="inline"><mml:mi>y</mml:mi></mml:math></inline-formula>-intercept, where an intercept of 0 corresponds to a slope of <inline-formula><mml:math id="M102" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>obs</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> over <inline-formula><mml:math id="M103" display="inline"><mml:msub><mml:mrow><mml:mfenced open="[" close="" separators="|"><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow></mml:mfenced><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> equivalent to the inactivation efficiency (<italic toggle="yes">i.e</italic>. the potency of the irreversible inhibitor).<sup><xref rid="R77" ref-type="bibr">77</xref></sup> For the three-step paradigm (<xref rid="FD2" ref-type="disp-formula">Scheme 2</xref>),
<disp-formula id="FD17"><label>(12)</label><mml:math id="M104" display="block"><mml:mrow><mml:msub><mml:mrow><mml:mtext>Eff</mml:mtext></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mtext>I</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow><mml:mspace linebreak="newline"/><mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mtext>r</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mtext>nr</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mtext>r</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula>
The probability distribution of the intermediates has a significant role in the potency of inhibition despite the non-limiting magnitude of the arming and disarming rate constants. From an empirical perspective, the probability distribution between conformations limits inhibition by linearly scaling the maximal observed rate constant. <inline-formula><mml:math id="M105" display="inline"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> also depends linearly on <inline-formula><mml:math id="M106" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, with,
<disp-formula id="FD18"><label>(13)</label><mml:math id="M107" display="block"><mml:munder><mml:mrow><mml:mtext>lim</mml:mtext></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>&#8594;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:munder><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:math></disp-formula>
and
<disp-formula id="FD19"><label>(14)</label><mml:math id="M108" display="block"><mml:munder><mml:mrow><mml:mtext>lim</mml:mtext></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>&#8594;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munder><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula>
Rearranging <xref rid="FD19" ref-type="disp-formula">eq 14</xref> for <inline-formula><mml:math id="M109" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> shows that <inline-formula><mml:math id="M110" display="inline"><mml:msub><mml:mrow><mml:mtext>Eff</mml:mtext></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> approaches <inline-formula><mml:math id="M111" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> as <inline-formula><mml:math id="M112" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> approaches 1; a reminder that simplifying <xref rid="FD17" ref-type="disp-formula">eq 12</xref> at <inline-formula><mml:math id="M113" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula> yields <inline-formula><mml:math id="M114" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula>. The dramatic relationship between simulated empirical data from the numerical solution to the ODEs of <xref rid="FD7" ref-type="disp-formula">Scheme 3</xref> and <inline-formula><mml:math id="M115" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is illustrated in <xref rid="F3" ref-type="fig">Figure 3</xref>.</p></sec><sec id="S9"><title>Dose-response analysis</title><p id="P18">The dose-dependence of irreversible kinetics can alternatively be examined with a dose-response curve. Unlike reversible kinetics, the dose-response must be examined under non-equilibrium conditions where the reaction is stopped before completion. For simplicity, we will only consider noncompetitive experimental procedures where some proportional marker of covalent occupancy, <italic toggle="yes">i.e</italic>. response, would be measured at the same timepoint for an array of saturating ligand concentrations. While the numerical simulations of the ODEs provides the most faithful representation of a given kinetic scheme, the familiar Hill equation,<sup><xref rid="R78" ref-type="bibr">78</xref></sup>
<disp-formula id="FD20"><label>(15)</label><mml:math id="M116" display="block"><mml:mtext>Response</mml:mtext><mml:mfenced separators="|"><mml:mrow><mml:mo>[</mml:mo><mml:mo>I</mml:mo><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>&#955;</mml:mi></mml:mrow><mml:mrow><mml:mtext>DR</mml:mtext></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:math></disp-formula>
can serve as a useful shorthand analytical framework for describing the dose-dependence data because it produces a simple sigmoidal curve with clearly identified parameters. In <xref rid="FD20" ref-type="disp-formula">eq 15</xref>, <inline-formula><mml:math id="M117" display="inline"><mml:msub><mml:mrow><mml:mi>&#955;</mml:mi></mml:mrow><mml:mrow><mml:mtext>DR</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> represents a scaling factor to match the arbitrary amplitude of the data, <inline-formula><mml:math id="M118" display="inline"><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> represents the dose that yields half the maximal scaled response, and <inline-formula><mml:math id="M119" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> represents the Hill coefficient.</p><p id="P19">The Hill equation works exceedingly well for reversible one-step systems measured at equilibrium, where the <inline-formula><mml:math id="M120" display="inline"><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> approximately equals the apparent binding affinity, <inline-formula><mml:math id="M121" display="inline"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>&#8776;</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> (<italic toggle="yes">i.e</italic>. the apparent inhibition constant, <inline-formula><mml:math id="M122" display="inline"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula>). However, special attention is required in the case of a covalent inhibitor because the covalent occupancy becomes truly stable only when the entire enzyme population has been irreversibly occupied. Thus, the value of <inline-formula><mml:math id="M123" display="inline"><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is time-dependent and its kinetic significance is ambiguous.<sup><xref rid="R61" ref-type="bibr">61</xref>,<xref rid="R69" ref-type="bibr">69</xref></sup> In the following, we assess those kinetic parameters in terms of <inline-formula><mml:math id="M124" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="M125" display="inline"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> for the purpose of describing dose-dependence data for a covalent inhibitor.</p><p id="P20">First, the expression must be properly normalized to covalent occupancy. This can be done with the exponential growth factor for approximating a time-response curve of covalent occupancy (<xref rid="FD14" ref-type="disp-formula">eq 9</xref>). Recall the empirical definition of <inline-formula><mml:math id="M126" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula>: the maximal observed rate constant that occurs when <inline-formula><mml:math id="M127" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mo>[</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mo>]</mml:mo></mml:math></inline-formula> is large enough to instantly and steadily force the entire (remaining) protein population into the reversibly-bound state. The Hill equation is then scaled by the maximal covalent occupancy achieved within the dose-response time limit <inline-formula><mml:math id="M128" display="inline"><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mtext>DR</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math></inline-formula> to get,
<disp-formula id="FD21"><label>(16)</label><mml:math id="M129" display="block"><mml:mtext>CO</mml:mtext><mml:mfenced separators="|"><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mtext>DR</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mo>[</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:math></disp-formula>
Thus, the amplitude of <xref rid="FD21" ref-type="disp-formula">eq 16</xref>, <italic toggle="yes">i.e</italic>. the limit of covalent occupancy given a set time and an infinitely high dose, is solely dependent on <inline-formula><mml:math id="M130" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> (or by extension <inline-formula><mml:math id="M131" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M132" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>).</p><p id="P21">To characterize the impact of the kinetic parameters on the location of the inflection point of <xref rid="FD21" ref-type="disp-formula">eq 16</xref>, <italic toggle="yes">i.e</italic>. the dose required for half-maximal covalent occupancy within the time limit, we solve for the isosurface of <inline-formula><mml:math id="M133" display="inline"><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> in terms of <inline-formula><mml:math id="M134" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="M135" display="inline"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula>. We start by solving for <inline-formula><mml:math id="M136" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>obs</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> from the concentration at half maximum inhibition, defining <inline-formula><mml:math id="M137" display="inline"><mml:mo>[</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>. Using the definition of the <inline-formula><mml:math id="M138" display="inline"><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, a relationship of familiar first-order growth factors can be expressed at this condition,
<disp-formula id="FD22"><label>(17)</label><mml:math id="M139" display="block"><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>obs</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mtext>DR</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:mfenced separators="|"><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mtext>DR</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow></mml:mfenced></mml:math></disp-formula>
We then solve for <inline-formula><mml:math id="M140" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>obs</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula>,
<disp-formula id="FD23"><label>(18)</label><mml:math id="M141" display="block"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>obs</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>&#951;</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mtext>DR</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula>
where
<disp-formula id="FD24"><label>(19)</label><mml:math id="M142" display="block"><mml:msub><mml:mrow><mml:mi>&#951;</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mtext>ln</mml:mtext><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mtext>DR</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:math></disp-formula>
Then, we substitute <inline-formula><mml:math id="M143" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>obs</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> with the Michaelis-Menten analog (<xref rid="FD15" ref-type="disp-formula">eq 10</xref>) when <inline-formula><mml:math id="M144" display="inline"><mml:mo>[</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> to get the approximation,
<disp-formula id="FD25"><label>(20)</label><mml:math id="M145" display="block"><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#8776;</mml:mo><mml:mfrac><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>&#951;</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mtext>DR</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula>
Finally, we solve for the <inline-formula><mml:math id="M146" display="inline"><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>,
<disp-formula id="FD26"><label>(21)</label><mml:math id="M147" display="block"><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mo>&#8776;</mml:mo><mml:mfrac><mml:mrow><mml:mo>-</mml:mo><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi>&#951;</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mtext>DR</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>&#951;</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math></disp-formula>
As is expected from reversible one-step kinetics, the <inline-formula><mml:math id="M148" display="inline"><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> approaches the reversible binding affinity, <inline-formula><mml:math id="M149" display="inline"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, as <inline-formula><mml:math id="M150" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> approaches 0. This expression of the <inline-formula><mml:math id="M151" display="inline"><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> is substituted into <xref rid="FD21" ref-type="disp-formula">eq 16</xref> to guide the understanding of dose-dependence with respect to the microscopic kinetic parameters of irreversible binding.</p><p id="P22">Still, this expression is an approximation of the kinetics. Covalent occupancy calculated from <xref rid="FD21" ref-type="disp-formula">eq 16</xref> and ODE-based simulations of <xref rid="FD7" ref-type="disp-formula">Scheme 3</xref> is compared in <xref rid="F4" ref-type="fig">Figure 4</xref> for three demonstrative cases. The same rate constants are used in both solutions for each case, and the value of <inline-formula><mml:math id="M152" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> in <xref rid="FD21" ref-type="disp-formula">eq 16</xref> is fit to the simulated covalent occupancy. <xref rid="FD21" ref-type="disp-formula">eq 16</xref> deviates from the numerical covalent occupancy in Cases 1 and 3. Case 1 represents the regime where <inline-formula><mml:math id="M153" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula>. In this regime, a single dose-response is likely not enough to resolve these rate constants anyway. Case 3 includes nonlinear effects from the bimolecular association step. The nonlinearity violates the first-order approximation used to derive <xref rid="FD26" ref-type="disp-formula">eq 21</xref>, and therefore leads to a poor analytical prediction of the <inline-formula><mml:math id="M154" display="inline"><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>.</p><p id="P23">According to the present analysis, the <inline-formula><mml:math id="M155" display="inline"><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> depends both on <inline-formula><mml:math id="M156" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="M157" display="inline"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula>. A smaller <inline-formula><mml:math id="M158" display="inline"><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> can either be attributed to a smaller <inline-formula><mml:math id="M159" display="inline"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> (or faster <inline-formula><mml:math id="M160" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> for systems lacking reversible equilibrium), larger <inline-formula><mml:math id="M161" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, or faster <inline-formula><mml:math id="M162" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula>. Therefore, the <inline-formula><mml:math id="M163" display="inline"><mml:msub><mml:mrow><mml:mtext>EC</mml:mtext></mml:mrow><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> by itself is a vague and possibly misleading parameter for evaluating irreversible systems. This mathematical analysis is illustrated with numerical kinetic simulations in <xref rid="F5" ref-type="fig">Figure 5</xref>.</p><p id="P24">The amplitude and inflection point of <xref rid="FD21" ref-type="disp-formula">eq 16</xref> taken together reveal the unique roles of <inline-formula><mml:math id="M164" display="inline"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="M165" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, and <inline-formula><mml:math id="M166" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula>. As shown in <xref rid="F5" ref-type="fig">Figure 5</xref>, proportional variations of these simulation parameters distinctly affect the dose-response curves. The lack of complete covariance for these parameters suggests that fitting dose-dependent data with parameterized simulations is a viable strategy for empirical approximation of <inline-formula><mml:math id="M167" display="inline"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, <inline-formula><mml:math id="M168" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, and <inline-formula><mml:math id="M169" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula>. If a set of dose-response curves (for different, <italic toggle="yes">e.g</italic>., experimental conditions or inhibitor modifications) is used in the fitting process, then one may discern the conditional impact on each parameter. If <inline-formula><mml:math id="M170" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> is predicted with molecular simulations and held fixed, then <inline-formula><mml:math id="M171" display="inline"><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M172" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> could be approximated from a single dose-response curve.</p><p id="P25">The dose-response simulations also demonstrate the importance of a well-chosen timepoint. If <inline-formula><mml:math id="M173" display="inline"><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mtext>DR</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> is too short, as is shown in <xref rid="F5" ref-type="fig">Figure 5</xref> (top row), then the analysis of covalent occupancy is more obscured by absolute sources of error. If <inline-formula><mml:math id="M174" display="inline"><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mtext>DR</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> is too long and the reaction reaches 100% covalent occupancy, as is shown in <xref rid="F5" ref-type="fig">Figure 5</xref> (bottom row), then <inline-formula><mml:math id="M175" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="M176" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> cannot be resolved in the fitting process.</p><p id="P26">By separating the contribution of rapid intermediates (<italic toggle="yes">e.g</italic>. conformations of the warhead or target residue, translation of the scaffold, protonation states) from the dissociation and inactivation steps, the kinetic comparisons between drug candidates become more precise, which should make it more straightforward to associate molecular characteristics with more potent and selective inhibition. This is especially beneficial when observed rates from reactivity or non-specific binding assays do not correlate with observed rates of inactivation or when the covalent action displays nonlinear complexities (as is the case for lysine-binders).<sup><xref rid="R52" ref-type="bibr">52</xref>,<xref rid="R79" ref-type="bibr">79</xref></sup></p><p id="P27">While <xref rid="FD21" ref-type="disp-formula">eq 16</xref> is a useful approximation expressing the relationships between covalent occupancy and kinetic parameters, <italic toggle="yes">in vitro</italic> kinetics are more accurately represented with ODE-based simulations. This avoids the vague nature of the Hill coefficient <inline-formula><mml:math id="M177" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> for fitting irreversible kinetics since noncooperative causes of a fitted <inline-formula><mml:math id="M178" display="inline"><mml:mi>n</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:math></inline-formula>, <italic toggle="yes">e.g</italic>. ultrasensitivity and significant depletion of [I], are unlikely to symmetrically affect the dose-response around the midpoint in the manner <inline-formula><mml:math id="M179" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> is designed to modulate.<sup><xref rid="R80" ref-type="bibr">80</xref>,<xref rid="R81" ref-type="bibr">81</xref></sup> ODE-based simulations also sidestep the assumptions and limitations of a pseudo-first order model such as the exponential growth factor,
<disp-formula id="FD27"><label>(22)</label><mml:math id="M180" display="block"><mml:mtext>CO</mml:mtext><mml:mfenced separators="|"><mml:mrow><mml:mo>[</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>&#8776;</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>obs</mml:mtext></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mtext>DR</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:msup></mml:math></disp-formula>
where <inline-formula><mml:math id="M181" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>obs</mml:mtext></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math></inline-formula> uses <xref rid="FD15" ref-type="disp-formula">eq 10</xref>. This extends to the dose-rate analysis using a time-dependent growth factor (<xref rid="FD14" ref-type="disp-formula">eq 9</xref>) and <xref rid="FD15" ref-type="disp-formula">eq 10</xref>.</p><p id="P28">If one globally fits parameterized simulations to multiple time-responses across varying doses&#8212;data required for dose-rate analysis anyway&#8212;then the fitting quality is no longer dependent on a single, well-chosen timepoint. The dose-dependence is included without the loss of information that occurs when an entire time course is compressed into a single value of <inline-formula><mml:math id="M182" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>obs</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula>. Since ODE-based simulations accommodate low doses without concern for the validity of a first-order approximation, this strategy may enable a more accurate and practical (especially if <inline-formula><mml:math id="M183" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>obs</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> would only plateau at unreasonably high doses) estimation of <inline-formula><mml:math id="M184" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="M185" display="inline"><mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">I</mml:mi></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup></mml:math></inline-formula> compared to the dose-rate workflow. The estimation of inactivation efficiency is also likely to be more accurate, because the initial slope of <inline-formula><mml:math id="M186" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>obs</mml:mtext></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mo>[</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:math></inline-formula> is susceptible to the nonlinearity of the bimolecular association step that emerges at low doses.</p><p id="P29">In ending this discussion, it is important to recall that the present analysis is meant to serve mainly as a conceptual illustration of how microscopic factors, that are not immediately related to the warhead&#8217;s chemistry, can impact the apparent observables such as the inhibition rate and residence time. Clearly, even with the expanded associated-unlinked intermediate state, <xref rid="FD2" ref-type="disp-formula">Scheme 2</xref> remains fairly simple and is unable to account for all the complex microscopic aspects of covalent inhibition encountered with different warheads. Expanding this type of analysis to realistic situations requires detailed atomic studies of the inhibition mechanism for specific cases. As an example, we previously represented the overall time-course of inhibition of BTK by ibrutinib, which targets a conserved cysteine residue, using an elaborate multi-state kinetic scheme based on the wealth of information extracted from QM/MM simulations.<sup><xref rid="R52" ref-type="bibr">52</xref></sup> The mechanisms and reaction pathways of other cysteine-targeting covalent inhibitors could be examined using a similar strategy.<sup><xref rid="R82" ref-type="bibr">82</xref>,<xref rid="R83" ref-type="bibr">83</xref></sup> Beyond cysteines, an understanding of covalent inhibition in the case of lysine-targeting warheads<sup><xref rid="R84" ref-type="bibr">84</xref></sup> or other chemistries<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup> will require detailed atomic studies.</p></sec></sec></sec><sec id="S10"><title>Conclusion</title><p id="P30">A critical issue with the minimal two-step kinetic model, which represents the process of covalent inhibition as an association followed by formation of a chemical bond, is that it may obscure important microscopic factors that affect the apparent efficiency of a lead compounds. The propensity of the warhead and the target residue to adopt a reaction-ready configuration affects the apparent rate of inhibition but is not, in fact, specifically related to the warhead itself. The lack of clarity may on this issue and misinterpretation of experimental kinetic data can, in turn, misdirect the design strategy and pull a project away from a productive direction. To make judicious design decisions, it is critical to draw accurate lessons from experimental data. To this end, we explored a more realistic kinetic scheme, which can be used as a framework to incorporate information about the fluctuations of the associated-unlinked inhibitor generated from classical MD simulations. Analysis based on numerical simulations showed that rapidly-equilibrating intermediate taking place on a short timescale can dramatically affect the apparent inhibition rate via the relative population of a reactive v.s. nonreactive configurations. Explicitly including the probability distribution of these states also refines the values of dissociation and inactivation rate constants, informing for example the amount of inactivation efficiency that can be attributed to only the warhead. Optimizing drug candidates with knowledge of the factors associated to the rapid fluctuations of the associated-unlinked inhibitor may offer a promising route for improving the apparent inactivation rate, while ignoring those could lead one to erroneously attribute a poor apparent inactivation efficiency to the warhead chemistry itself. Refining the evaluation with computational prediction of noncovalent behavior can provide a more precise evaluation of a drug&#8217;s potential and streamline drug optimization. Further work to develop kinetic frameworks incorporating microscopic states gleaned from classical MD simulations may be able to provide a more precise understanding of the molecular characteristics underlying apparent kinetic parameters.</p></sec></body><back><ack id="S12"><title>Acknowledgement</title><p id="P32">The authors thank Dr. Trayder Thomas and Prof. Raymond Moellering for the helpful discussion. This research was supported by the National Institutes of Health (NIH) via grant CA093577.</p></ack><sec sec-type="data-availability" id="S11"><title>Data and Software Availability</title><p id="P31">A Jupyter notebook for the kinetic modeling is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/RouxLab/covalent-kinetics-with-rapid-intermediates-2025" ext-link-type="uri">https://github.com/RouxLab/covalent-kinetics-with-rapid-intermediates-2025</ext-link>. All data is deterministically generated therein. The in-house Python package for simulating the kinetics is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/kghaby/GeKiM" ext-link-type="uri">https://github.com/kghaby/GeKiM</ext-link>.</p></sec><ref-list><title>References</title><ref id="R1"><label>(1)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Baker</surname><given-names>B. R.</given-names></name><article-title>Factors in the Design of Active-Site-Directed Irreversible Inhibitors</article-title>. <source>Journal of Pharmaceutical Sciences</source><year>1964</year>, <volume>53</volume>, <fpage>347</fpage>&#8211;<lpage>364</lpage>.<pub-id pub-id-type="pmid">14189924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.2600530402</pub-id></mixed-citation></ref><ref id="R2"><label>(2)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Proudfoot</surname><given-names>A. T.</given-names></name>; <name name-style="western"><surname>Wright</surname><given-names>N.</given-names></name><article-title>Acute Paracetamol Poisoning</article-title>. <source>British Medical Journal</source><year>1970</year>, <volume>3</volume>, <fpage>557</fpage>&#8211;<lpage>558</lpage>.<pub-id pub-id-type="pmid">5311516</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.3.5722.557</pub-id><pub-id pub-id-type="pmcid">PMC1701561</pub-id></mixed-citation></ref><ref id="R3"><label>(3)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Singh</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Petter</surname><given-names>R. C.</given-names></name>; <name name-style="western"><surname>Baillie</surname><given-names>T. A.</given-names></name>; <name name-style="western"><surname>Whitty</surname><given-names>A.</given-names></name><article-title>The Resurgence of Covalent Drugs</article-title>. <source>Nat Rev Drug Discov</source><year>2011</year>, <volume>10</volume>, <fpage>307</fpage>&#8211;<lpage>317</lpage>.<pub-id pub-id-type="pmid">21455239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd3410</pub-id></mixed-citation></ref><ref id="R4"><label>(4)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mah</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Thomas</surname><given-names>J. R.</given-names></name>; <name name-style="western"><surname>Shafer</surname><given-names>C. M.</given-names></name><article-title>Drug Discovery Considerations in the Development of Covalent Inhibitors</article-title>. <source>Bioorg Med Chem Lett</source><year>2014</year>, <volume>24</volume>, <fpage>33</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="pmid">24314671</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmcl.2013.10.003</pub-id></mixed-citation></ref><ref id="R5"><label>(5)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bauer</surname><given-names>R. A.</given-names></name><article-title>Covalent Inhibitors in Drug Discovery: From Accidental Discoveries to Avoided Liabilities and Designed Therapies</article-title>. <source>Drug Discov Today</source><year>2015</year>, <volume>20</volume>, <fpage>1061</fpage>&#8211;<lpage>1073</lpage>.<pub-id pub-id-type="pmid">26002380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2015.05.005</pub-id></mixed-citation></ref><ref id="R6"><label>(6)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gonz&#225;lez-Bello</surname><given-names>C.</given-names></name><article-title>Designing Irreversible Inhibitors&#8212;Worth the Effort?</article-title><source>ChemMedChem</source><year>2016</year>, <volume>11</volume>, <fpage>22</fpage>&#8211;<lpage>30</lpage>.<pub-id pub-id-type="pmid">26593241</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cmdc.201500469</pub-id></mixed-citation></ref><ref id="R7"><label>(7)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Hatcher</surname><given-names>J. M.</given-names></name>; <name name-style="western"><surname>Teng</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Gray</surname><given-names>N. S.</given-names></name>; <name name-style="western"><surname>Kostic</surname><given-names>M.</given-names></name><article-title>Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation</article-title>. <source>Cell Chemical Biology</source><year>2019</year>, <volume>26</volume>, <fpage>1486</fpage>&#8211;<lpage>1500</lpage>.<pub-id pub-id-type="pmid">31631011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chembiol.2019.09.012</pub-id><pub-id pub-id-type="pmcid">PMC6886688</pub-id></mixed-citation></ref><ref id="R8"><label>(8)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ghosh</surname><given-names>A. K.</given-names></name>; <name name-style="western"><surname>Samanta</surname><given-names>I.</given-names></name>; <name name-style="western"><surname>Mondal</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>W. R.</given-names></name><article-title>Covalent Inhibition in Drug Discovery</article-title>. <source>ChemMedChem</source><year>2019</year>, <volume>14</volume>, <fpage>889</fpage>&#8211;<lpage>906</lpage>.<pub-id pub-id-type="pmid">30816012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cmdc.201900107</pub-id><pub-id pub-id-type="pmcid">PMC6816337</pub-id></mixed-citation></ref><ref id="R9"><label>(9)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Krantz</surname><given-names>A.</given-names></name><article-title>A Classification of Enzyme Inhibitors</article-title>. <source>Bioorganic &amp; Medicinal Chemistry Letters</source><year>1992</year>, <volume>2</volume>, <fpage>1327</fpage>&#8211;<lpage>1334</lpage>.</mixed-citation></ref><ref id="R10"><label>(10)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Potashman</surname><given-names>M. H.</given-names></name>; <name name-style="western"><surname>Duggan</surname><given-names>M. E.</given-names></name><article-title>Covalent Modifiers: An Orthogonal Approach to Drug Design</article-title>. <source>Journal of Medicinal Chemistry</source><year>2009</year>, <volume>52</volume>, <fpage>1231</fpage>&#8211;<lpage>1246</lpage>.<pub-id pub-id-type="pmid">19203292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm8008597</pub-id></mixed-citation></ref><ref id="R11"><label>(11)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Smith</surname><given-names>A. J. T.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Leach</surname><given-names>A. G.</given-names></name>; <name name-style="western"><surname>Houk</surname><given-names>K. N.</given-names></name><article-title>Beyond Picomolar Affinities: Quantitative Aspects of Noncovalent and Covalent Binding of Drugs to Proteins</article-title>. <source>Journal of Medicinal Chemistry</source><year>2009</year>, <volume>52</volume>, <fpage>225</fpage>&#8211;<lpage>233</lpage>.<pub-id pub-id-type="pmid">19053779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jm800498e</pub-id><pub-id pub-id-type="pmcid">PMC2646787</pub-id></mixed-citation></ref><ref id="R12"><label>(12)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Johnson</surname><given-names>D. S.</given-names></name>; <name name-style="western"><surname>Weerapana</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Cravatt</surname><given-names>B. F.</given-names></name><article-title>Strategies for Discovering and Derisking Covalent, Irreversible Enzyme Inhibitors</article-title>. <source>Future Medicinal Chemistry</source><year>2010</year>, <volume>2</volume>, <fpage>949</fpage>&#8211;<lpage>964</lpage>.<pub-id pub-id-type="pmid">20640225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4155/fmc.10.21</pub-id><pub-id pub-id-type="pmcid">PMC2904065</pub-id></mixed-citation></ref><ref id="R13"><label>(13)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kalgutkar</surname><given-names>A. S.</given-names></name>; <name name-style="western"><surname>Dalvie</surname><given-names>D. K.</given-names></name><article-title>Drug Discovery for a New Generation of Covalent Drugs</article-title>. <source>Expert Opinion on Drug Discovery</source><year>2012</year>, <volume>7</volume>, <fpage>561</fpage>&#8211;<lpage>581</lpage>.<pub-id pub-id-type="pmid">22607458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17460441.2012.688744</pub-id></mixed-citation></ref><ref id="R14"><label>(14)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Niphakis</surname><given-names>M. J.</given-names></name>; <name name-style="western"><surname>Cravatt</surname><given-names>B. F.</given-names></name><article-title>Enzyme Inhibitor Discovery by Activity-Based Protein Profiling</article-title>. <source>Annual Review of Biochemistry</source><year>2014</year>, <volume>83</volume>, <fpage>341</fpage>&#8211;<lpage>377</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-biochem-060713-035708</pub-id><pub-id pub-id-type="pmid">24905785</pub-id></mixed-citation></ref><ref id="R15"><label>(15)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Visscher</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Arkin</surname><given-names>M. R.</given-names></name>; <name name-style="western"><surname>Dansen</surname><given-names>T. B.</given-names></name><article-title>Covalent Targeting of Acquired Cysteines in Cancer</article-title>. <source>Current Opinion in Chemical Biology</source><year>2016</year>, <volume>30</volume>, <fpage>61</fpage>&#8211;<lpage>67</lpage>.<pub-id pub-id-type="pmid">26629855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cbpa.2015.11.004</pub-id><pub-id pub-id-type="pmcid">PMC4731306</pub-id></mixed-citation></ref><ref id="R16"><label>(16)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Baillie</surname><given-names>T. A.</given-names></name><article-title>Targeted Covalent Inhibitors for Drug Design</article-title>. <source>Angewandte Chemie International Edition</source><year>2016</year>, <volume>55</volume>, <fpage>13408</fpage>&#8211;<lpage>13421</lpage>.<pub-id pub-id-type="pmid">27539547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/anie.201601091</pub-id></mixed-citation></ref><ref id="R17"><label>(17)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bandyopadhyay</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><article-title>Targeting Biomolecules with Reversible Covalent Chemistry</article-title>. <source>Current Opinion in Chemical Biology</source><year>2016</year>, <volume>34</volume>, <fpage>110</fpage>&#8211;<lpage>116</lpage>.<pub-id pub-id-type="pmid">27599186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cbpa.2016.08.011</pub-id><pub-id pub-id-type="pmcid">PMC5107367</pub-id></mixed-citation></ref><ref id="R18"><label>(18)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>De Cesco</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Kurian</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Dufresne</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Mittermaier</surname><given-names>A. K.</given-names></name>; <name name-style="western"><surname>Moitessier</surname><given-names>N.</given-names></name><article-title>Covalent Inhibitors Design and Discovery</article-title>. <source>European Journal of Medicinal Chemistry</source><year>2017</year>, <volume>138</volume>, <fpage>96</fpage>&#8211;<lpage>114</lpage>.<pub-id pub-id-type="pmid">28651155</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2017.06.019</pub-id></mixed-citation></ref><ref id="R19"><label>(19)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jackson</surname><given-names>P. A.</given-names></name>; <name name-style="western"><surname>Widen</surname><given-names>J. C.</given-names></name>; <name name-style="western"><surname>Harki</surname><given-names>D. A.</given-names></name>; <name name-style="western"><surname>Brummond</surname><given-names>K. M.</given-names></name><article-title>Covalent Modifiers: A Chemical Perspective on the Reactivity of <italic toggle="yes">&#945;</italic>, <italic toggle="yes">&#946;</italic>-Unsaturated Carbonyls With Thiols via Hetero-Michael Addition Reactions</article-title>. <source>Journal of Medicinal Chemistry</source><year>2017</year>, <volume>60</volume>, <fpage>839</fpage>&#8211;<lpage>885</lpage>.<pub-id pub-id-type="pmid">27996267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.6b00788</pub-id><pub-id pub-id-type="pmcid">PMC5308545</pub-id></mixed-citation></ref><ref id="R20"><label>(20)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lagoutte</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Patouret</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Winssinger</surname><given-names>N.</given-names></name><article-title>Covalent Inhibitors: An Opportunity for Rational Target Selectivity</article-title>. <source>Current Opinion in Chemical Biology</source><year>2017</year>, <volume>39</volume>, <fpage>54</fpage>&#8211;<lpage>63</lpage>.<pub-id pub-id-type="pmid">28609675</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cbpa.2017.05.008</pub-id></mixed-citation></ref><ref id="R21"><label>(21)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><article-title>Designed Covalent Allosteric Modulators: An Emerging Paradigm in Drug Discovery</article-title>. <source>Drug Discovery Today</source><year>2017</year>, <volume>22</volume>, <fpage>447</fpage>&#8211;<lpage>453</lpage>.<pub-id pub-id-type="pmid">27888140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drudis.2016.11.013</pub-id></mixed-citation></ref><ref id="R22"><label>(22)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mukherjee</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Grimster</surname><given-names>N. P.</given-names></name><article-title>Beyond Cysteine: Recent Developments in the Area of Targeted Covalent Inhibition</article-title>. <source>Current Opinion in Chemical Biology</source><year>2018</year>, <volume>44</volume>, <fpage>30</fpage>&#8211;<lpage>38</lpage>.<pub-id pub-id-type="pmid">29857316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cbpa.2018.05.011</pub-id></mixed-citation></ref><ref id="R23"><label>(23)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lonsdale</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Ward</surname><given-names>R. A.</given-names></name><article-title>Structure-Based Design of Targeted Covalent Inhibitors</article-title>. <source>Chemical Society Reviews</source><year>2018</year>, <volume>47</volume>, <fpage>3816</fpage>&#8211;<lpage>3830</lpage>.<pub-id pub-id-type="pmid">29620097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c7cs00220c</pub-id></mixed-citation></ref><ref id="R24"><label>(24)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Boike</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Henning</surname><given-names>N. J.</given-names></name>; <name name-style="western"><surname>Nomura</surname><given-names>D. K.</given-names></name><article-title>Advances in Covalent Drug Discovery</article-title>. <source>Nat Rev Drug Discov</source><year>2022</year>, <volume>21</volume>, <fpage>881</fpage>&#8211;<lpage>898</lpage>.<pub-id pub-id-type="pmid">36008483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41573-022-00542-z</pub-id><pub-id pub-id-type="pmcid">PMC9403961</pub-id></mixed-citation></ref><ref id="R25"><label>(25)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Faridoon</surname></name>; <name name-style="western"><surname>Ng</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Li</surname><given-names>J. J.</given-names></name><article-title>An Update on the Discovery and Development of Reversible Covalent Inhibitors</article-title>. <source>Medicinal Chemistry Research</source><year>2023</year>, <volume>32</volume>, <fpage>1039</fpage>&#8211;<lpage>1062</lpage>.<pub-id pub-id-type="pmid">37305209</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00044-023-03065-3</pub-id><pub-id pub-id-type="pmcid">PMC10148018</pub-id></mixed-citation></ref><ref id="R26"><label>(26)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hameed</surname><given-names>M. S.</given-names></name>; <name name-style="western"><surname>Cao</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Zeng</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Ren</surname><given-names>Y.</given-names></name><article-title>Advancements, Challenges, and Future Frontiers in Covalent Inhibitors and Covalent Drugs: A Review</article-title>. <source>European Journal of Medicinal Chemistry Reports</source><year>2024</year>, <volume>12</volume>, <fpage>100217</fpage>.</mixed-citation></ref><ref id="R27"><label>(27)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>M&#252;ller</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Sennhenn</surname><given-names>P. C.</given-names></name>; <name name-style="western"><surname>Woodcock</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Neumann</surname><given-names>L.</given-names></name><article-title>The &#8216;Retro-Design&#8217; Concept for Novel Kinase Inhibitors</article-title>. <source>IDrugs</source><year>2010</year>, <volume>13</volume>, <fpage>457</fpage>&#8211;<lpage>466</lpage>.<pub-id pub-id-type="pmid">20582870</pub-id></mixed-citation></ref><ref id="R28"><label>(28)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Tonge</surname><given-names>P. J.</given-names></name><article-title>Drug-Target Residence Time: Critical Information for Lead Optimization</article-title>. <source>Curr Opin Chem Biol</source><year>2010</year>, <volume>14</volume>, <fpage>467</fpage>&#8211;<lpage>474</lpage>.<pub-id pub-id-type="pmid">20663707</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cbpa.2010.06.176</pub-id><pub-id pub-id-type="pmcid">PMC2918722</pub-id></mixed-citation></ref><ref id="R29"><label>(29)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Ouyang</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Wan</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Gajiwala</surname><given-names>K. S.</given-names></name>; <name name-style="western"><surname>Kath</surname><given-names>J. C.</given-names></name>; <name name-style="western"><surname>Jones</surname><given-names>L. H.</given-names></name>; <name name-style="western"><surname>Burlingame</surname><given-names>A. L.</given-names></name>; <name name-style="western"><surname>Taunton</surname><given-names>J.</given-names></name><article-title>Broad-Spectrum Kinase Profiling in Live Cells With Lysine-Targeted Sulfonyl Fluoride Probes</article-title>. <source>J Am Chem Soc</source><year>2017</year>, <volume>139</volume>, <fpage>680</fpage>&#8211;<lpage>685</lpage>.<pub-id pub-id-type="pmid">28051857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/jacs.6b08536</pub-id><pub-id pub-id-type="pmcid">PMC5858558</pub-id></mixed-citation></ref><ref id="R30"><label>(30)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Awoonor-Williams</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Walsh</surname><given-names>A. G.</given-names></name>; <name name-style="western"><surname>Rowley</surname><given-names>C. N.</given-names></name><article-title>Modeling Covalent-Modifier Drugs</article-title>. <source>Biochim Biophys Acta Proteins Proteom</source><year>2017</year>, <volume>1865</volume>, <fpage>1664</fpage>&#8211;<lpage>1675</lpage>.<pub-id pub-id-type="pmid">28528876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbapap.2017.05.009</pub-id></mixed-citation></ref><ref id="R31"><label>(31)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tuley</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Fast</surname><given-names>W.</given-names></name><article-title>The Taxonomy of Covalent Inhibitors</article-title>. <source>Biochemistry</source><year>2018</year>, <volume>57</volume>, <fpage>3326</fpage>&#8211;<lpage>3337</lpage>.<pub-id pub-id-type="pmid">29689165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.biochem.8b00315</pub-id><pub-id pub-id-type="pmcid">PMC6016374</pub-id></mixed-citation></ref><ref id="R32"><label>(32)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Martin</surname><given-names>J. S.</given-names></name>; <name name-style="western"><surname>MacKenzie</surname><given-names>C. J.</given-names></name>; <name name-style="western"><surname>Fletcher</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Gilbert</surname><given-names>I. H.</given-names></name><article-title>Characterising Covalent Warhead Reactivity</article-title>. <source>Bioorganic &amp; Medicinal Chemistry</source><year>2019</year>, <volume>27</volume>, <fpage>2066</fpage>&#8211;<lpage>2074</lpage>.<pub-id pub-id-type="pmid">30975501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bmc.2019.04.002</pub-id><pub-id pub-id-type="pmcid">PMC6538824</pub-id></mixed-citation></ref><ref id="R33"><label>(33)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Abdeldayem</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Raouf</surname><given-names>Y. S.</given-names></name>; <name name-style="western"><surname>Constantinescu</surname><given-names>S. N.</given-names></name>; <name name-style="western"><surname>Moriggl</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Gunning</surname><given-names>P. T.</given-names></name><article-title>Advances in Covalent Kinase Inhibitors</article-title>. <source>Chemical Society Reviews</source><year>2020</year>, <volume>49</volume>, <fpage>2617</fpage>&#8211;<lpage>2687</lpage>.<pub-id pub-id-type="pmid">32227030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1039/c9cs00720b</pub-id></mixed-citation></ref><ref id="R34"><label>(34)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bianco</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Goodsell</surname><given-names>D. S.</given-names></name>; <name name-style="western"><surname>Forli</surname><given-names>S.</given-names></name><article-title>Selective and Effective: Current Progress in Computational Structure-Based Drug Discovery of Targeted Covalent Inhibitors</article-title>. <source>Trends in Pharmacological Sciences</source><year>2020</year>, <volume>41</volume>, <fpage>1038</fpage>&#8211;<lpage>1049</lpage>.<pub-id pub-id-type="pmid">33153778</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2020.10.005</pub-id><pub-id pub-id-type="pmcid">PMC7669701</pub-id></mixed-citation></ref><ref id="R35"><label>(35)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yoshimori</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Miljkovi&#263;</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Bajorath</surname><given-names>J.</given-names></name><article-title>Approach for the Design of Covalent Protein Kinase Inhibitors via Focused Deep Generative Modeling</article-title>. <source>Molecules</source><year>2022</year>, <volume>27</volume>, <fpage>570</fpage>.<pub-id pub-id-type="pmid">35056884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/molecules27020570</pub-id><pub-id pub-id-type="pmcid">PMC8778003</pub-id></mixed-citation></ref><ref id="R36"><label>(36)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hasan</surname><given-names>M. N.</given-names></name>; <name name-style="western"><surname>Ray</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Saha</surname><given-names>A.</given-names></name><article-title>Tools for Modeling Covalent Modification of Proteins: A Review on Computational Covalent Drug Discovery</article-title>. <source>J Phys Chem B</source><year>2023</year>, <volume>127</volume>, <fpage>9663</fpage>&#8211;<lpage>9684</lpage>.<pub-id pub-id-type="pmid">37921534</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jpcb.3c04710</pub-id></mixed-citation></ref><ref id="R37"><label>(37)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Schaefer</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Cheng</surname><given-names>X.</given-names></name><article-title>Recent Advances in Covalent Drug Discovery</article-title>. <source>Pharmaceuticals</source><year>2023</year>, <volume>16</volume>, <fpage>663</fpage>.<pub-id pub-id-type="pmid">37242447</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ph16050663</pub-id><pub-id pub-id-type="pmcid">PMC10220821</pub-id></mixed-citation></ref><ref id="R38"><label>(38)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Raouf</surname><given-names>Y. S.</given-names></name><article-title>Covalent Inhibitors: To Infinity and Beyond</article-title>. <source>Journal of Medicinal Chemistry</source><year>2024</year>, <volume>67</volume>, <fpage>10513</fpage>&#8211;<lpage>10516</lpage>.<pub-id pub-id-type="pmid">38913822</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.4c01308</pub-id></mixed-citation></ref><ref id="R39"><label>(39)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fradera</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Kaur</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Mestres</surname><given-names>J.</given-names></name><article-title>Unsupervised Guided Docking of Covalently Bound Ligands</article-title>. <source>J Comput Aided Mol Des</source><year>2004</year>, <volume>18</volume>, <fpage>635</fpage>&#8211;<lpage>650</lpage>.<pub-id pub-id-type="pmid">15849994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10822-004-5291-4</pub-id></mixed-citation></ref><ref id="R40"><label>(40)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>London</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Miller</surname><given-names>R. M.</given-names></name>; <name name-style="western"><surname>Krishnan</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Uchida</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Irwin</surname><given-names>J. J.</given-names></name>; <name name-style="western"><surname>Eidam</surname><given-names>O.</given-names></name>; <name name-style="western"><surname>Gibold</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>&#269;</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Bonnet</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Shoichet</surname><given-names>B. K.</given-names></name>; <name name-style="western"><surname>Taunton</surname><given-names>J.</given-names></name><article-title>Covalent Docking of Large Libraries for the Discovery of Chemical Probes</article-title>. <source>Nat Chem Biol</source><year>2014</year>, <volume>10</volume>, <fpage>1066</fpage>&#8211;<lpage>1072</lpage>.<pub-id pub-id-type="pmid">25344815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nchembio.1666</pub-id><pub-id pub-id-type="pmcid">PMC4232467</pub-id></mixed-citation></ref><ref id="R41"><label>(41)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Toledo Warshaviak</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Golan</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Borrelli</surname><given-names>K. W.</given-names></name>; <name name-style="western"><surname>Zhu</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Kalid</surname><given-names>O.</given-names></name><article-title>Structure-Based Virtual Screening Approach for Discovery of Covalently Bound Ligands</article-title>. <source>J Chem Inf Model</source><year>2014</year>, <volume>54</volume>, <fpage>1941</fpage>&#8211;<lpage>1950</lpage>.<pub-id pub-id-type="pmid">24932913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ci500175r</pub-id></mixed-citation></ref><ref id="R42"><label>(42)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhu</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Borrelli</surname><given-names>K. W.</given-names></name>; <name name-style="western"><surname>Greenwood</surname><given-names>J. R.</given-names></name>; <name name-style="western"><surname>Day</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Abel</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Farid</surname><given-names>R. S.</given-names></name>; <name name-style="western"><surname>Harder</surname><given-names>E.</given-names></name><article-title>Docking Covalent Inhibitors: A Parameter Free Approach to Pose Prediction and Scoring</article-title>. <source>J Chem Inf Model</source><year>2014</year>, <volume>54</volume>, <fpage>1932</fpage>&#8211;<lpage>1940</lpage>.<pub-id pub-id-type="pmid">24916536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ci500118s</pub-id></mixed-citation></ref><ref id="R43"><label>(43)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Scholz</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Knorr</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Hamacher</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Schmidt</surname><given-names>B.</given-names></name><article-title>DOCKTITE-a Highly Versatile Step-by-Step Workflow for Covalent Docking and Virtual Screening in the Molecular Operating Environment</article-title>. <source>J Chem Inf Model</source><year>2015</year>, <volume>55</volume>, <fpage>398</fpage>&#8211;<lpage>406</lpage>.<pub-id pub-id-type="pmid">25541749</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/ci500681r</pub-id></mixed-citation></ref><ref id="R44"><label>(44)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bianco</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Forli</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Goodsell</surname><given-names>D. S.</given-names></name>; <name name-style="western"><surname>Olson</surname><given-names>A. J.</given-names></name><article-title>Covalent Docking Using Autodock: Two-Point Attractor and Flexible Side Chain Methods</article-title>. <source>Protein Sci</source><year>2016</year>, <volume>25</volume>, <fpage>295</fpage>&#8211;<lpage>301</lpage>.<pub-id pub-id-type="pmid">26103917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pro.2733</pub-id><pub-id pub-id-type="pmcid">PMC4815316</pub-id></mixed-citation></ref><ref id="R45"><label>(45)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Moitessier</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Pottel</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Therrien</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Englebienne</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Tomberg</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Corbeil</surname><given-names>C. R.</given-names></name><article-title>Medicinal Chemistry Projects Requiring Imaginative Structure-Based Drug Design Methods</article-title>. <source>Acc Chem Res</source><year>2016</year>, <volume>49</volume>, <fpage>1646</fpage>&#8211;<lpage>1657</lpage>.<pub-id pub-id-type="pmid">27529781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.accounts.6b00185</pub-id></mixed-citation></ref><ref id="R46"><label>(46)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yu</surname><given-names>H. S.</given-names></name>; <name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Lupyan</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Kimura</surname><given-names>T.</given-names></name>; <name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Jacobson</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Harder</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Abel</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><article-title>Toward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics</article-title>. <source>J Chem Inf Model</source><year>2019</year>, <volume>59</volume>, <fpage>3955</fpage>&#8211;<lpage>3967</lpage>.<pub-id pub-id-type="pmid">31425654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.9b00268</pub-id></mixed-citation></ref><ref id="R47"><label>(47)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mihalovits</surname><given-names>L. M.</given-names></name>; <name name-style="western"><surname>Ferenczy</surname><given-names>G. G.</given-names></name>; <name name-style="western"><surname>Keser&#250;</surname><given-names>G. M.</given-names></name><article-title>Affinity and Selectivity Assessment of Covalent Inhibitors by Free Energy Calculations</article-title>. <source>J Chem Inf Model</source><year>2020</year>, <volume>60</volume>, <fpage>6579</fpage>&#8211;<lpage>6594</lpage>.<pub-id pub-id-type="pmid">33295760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.0c00834</pub-id></mixed-citation></ref><ref id="R48"><label>(48)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Awoonor-Williams</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Rowley</surname><given-names>C. N.</given-names></name><article-title>Modeling the Binding and Conformational Energetics of a Targeted Covalent Inhibitor to Bruton&#8217;s Tyrosine Kinase</article-title>. <source>J Chem Inf Model</source><year>2021</year>, <volume>61</volume>, <fpage>5234</fpage>&#8211;<lpage>5242</lpage>.<pub-id pub-id-type="pmid">34590480</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.1c00897</pub-id></mixed-citation></ref><ref id="R49"><label>(49)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Endres</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Yuan Chen</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Sotriffer</surname><given-names>C.</given-names></name><article-title>MD-Based Assessment of Covalent Inhibitors in Noncovalent Association Complexes: Learning From Cathepsin K as a Test Case</article-title>. <source>J Chem Inf Model</source><year>2023</year>, <volume>63</volume>, <fpage>3186</fpage>&#8211;<lpage>3197</lpage>.<pub-id pub-id-type="pmid">37165835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.3c00061</pub-id></mixed-citation></ref><ref id="R50"><label>(50)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name>; <name name-style="western"><surname>Vind</surname><given-names>A. C.</given-names></name>; <name name-style="western"><surname>Kong</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Song</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Tu</surname><given-names>Z.</given-names></name>; <name name-style="western"><surname>Yun</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Smaill</surname><given-names>J. B.</given-names></name>; <name name-style="western"><surname>Zhang</surname><given-names>Q.-W.</given-names></name>; <name name-style="western"><surname>Ding</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Bekker-Jensen</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><article-title>Rational Design of Covalent Kinase Inhibitors by an Integrated Computational Workflow (Kin-Cov)</article-title>. <source>Journal of Medicinal Chemistry</source><year>2023</year>, <volume>66</volume>, <fpage>7405</fpage>&#8211;<lpage>7420</lpage>.<pub-id pub-id-type="pmid">37220641</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jmedchem.3c00088</pub-id></mixed-citation></ref><ref id="R51"><label>(51)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lonsdale</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Burgess</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Colclough</surname><given-names>N.</given-names></name>; <name name-style="western"><surname>Davies</surname><given-names>N. L.</given-names></name>; <name name-style="western"><surname>Lenz</surname><given-names>E. M.</given-names></name>; <name name-style="western"><surname>Orton</surname><given-names>A. L.</given-names></name>; <name name-style="western"><surname>Ward</surname><given-names>R. A.</given-names></name><article-title>Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity</article-title>. <source>Journal of Chemical Information and Modeling</source><year>2017</year>, <volume>57</volume>, <fpage>3124</fpage>&#8211;<lpage>3137</lpage>.<pub-id pub-id-type="pmid">29131621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.7b00553</pub-id></mixed-citation></ref><ref id="R52"><label>(52)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Barragan</surname><given-names>A. M.</given-names></name>; <name name-style="western"><surname>Ghaby</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Pond</surname><given-names>M. P.</given-names></name>; <name name-style="western"><surname>Roux</surname><given-names>B.</given-names></name><article-title>Computational Investigation of the Covalent Inhibition Mechanism of Bruton&#8217;s Tyrosine Kinase by Ibrutinib</article-title>. <source>Journal of Chemical Information and Modeling</source><year>2024</year>, <volume>64</volume>, <fpage>3488</fpage>&#8211;<lpage>3502</lpage>.<pub-id pub-id-type="pmid">38546820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.4c00023</pub-id><pub-id pub-id-type="pmcid">PMC11386585</pub-id></mixed-citation></ref><ref id="R53"><label>(53)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Tan</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Hu</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Hussain</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Qiao</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Tu</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name>; <name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><article-title>Dynamics Playing a Key Role in the Covalent Binding of Inhibitors to Focal Adhesion Kinase</article-title>. <source>Journal of Chemical Information and Modeling</source><year>2024</year>, <volume>64</volume>, <fpage>6053</fpage>&#8211;<lpage>6061</lpage>.<pub-id pub-id-type="pmid">39051776</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.4c00418</pub-id></mixed-citation></ref><ref id="R54"><label>(54)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kitz</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Wilson</surname><given-names>I. B.</given-names></name><article-title>Esters of Methanesulfonic Acid as Irreversible Inhibitors of Acetylcholinesterase</article-title>. <source>J Biol Chem</source><year>1962</year>, <volume>237</volume>, <fpage>3245</fpage>&#8211;<lpage>3249</lpage>.<pub-id pub-id-type="pmid">14033211</pub-id></mixed-citation></ref><ref id="R55"><label>(55)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mayhew</surname><given-names>B. S.</given-names></name>; <name name-style="western"><surname>Jones</surname><given-names>D. R.</given-names></name>; <name name-style="western"><surname>Hall</surname><given-names>S. D.</given-names></name><article-title>An In Vitro Model for Predicting In Vivo Inhibition of Cytochrome P450 3A4 by Metabolic Intermediate Complex Formation</article-title>. <source>Drug Metabolism and Disposition</source><year>2000</year>, <volume>28</volume>, <fpage>1031</fpage>&#8211;<lpage>1037</lpage>.<pub-id pub-id-type="pmid">10950845</pub-id></mixed-citation></ref><ref id="R56"><label>(56)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mons</surname><given-names>E.</given-names></name>; <name name-style="western"><surname>Roet</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Kim</surname><given-names>R. Q.</given-names></name>; <name name-style="western"><surname>Mulder</surname><given-names>M. P. C.</given-names></name><article-title>A Comprehensive Guide for Assessing Covalent Inhibition in Enzymatic Assays Illustrated With Kinetic Simulations</article-title>. <source>Curr Protoc</source><year>2022</year>, <volume>2</volume>, <fpage>e419</fpage>.<pub-id pub-id-type="pmid">35671150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpz1.419</pub-id></mixed-citation></ref><ref id="R57"><label>(57)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Klinman</surname><given-names>J. P.</given-names></name>; <name name-style="western"><surname>Matthews</surname><given-names>R. G.</given-names></name><article-title>Calculation of Substrate Dissociation Constants from Steady-State Isotope Effects in Enzyme-Catalyzed Reactions</article-title>. <source>Journal of the American Chemical Society</source><year>1985</year>, <volume>107</volume>, <fpage>1058</fpage>&#8211;<lpage>1060</lpage>.</mixed-citation></ref><ref id="R58"><label>(58)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Teslenko</surname><given-names>V. I.</given-names></name>; <name name-style="western"><surname>Kapitanchuk</surname><given-names>O. L.</given-names></name><article-title>Dynamics of Transient Processes in Irreversible Kinetic Models</article-title>. <source>Ukr. J. Phys.</source><year>2012</year>, <volume>57</volume>.</mixed-citation></ref><ref id="R59"><label>(59)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bisi</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Loy</surname><given-names>N.</given-names></name><article-title>Kinetic Models for Systems of Interacting Agents with Multiple Microscopic States</article-title>. <source>Physica D: Nonlinear Phenomena</source><year>2024</year>, <volume>457</volume>, <fpage>133967</fpage>.</mixed-citation></ref><ref id="R60"><label>(60)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Estevez</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Vilanova</surname><given-names>E.</given-names></name><article-title>Model Equations for the Kinetics of Covalent Irreversible Enzyme Inhibition and Spontaneous Reactivation: Esterases and Organophosphorus Compounds</article-title>. <source>Critical Reviews in Toxicology</source><year>2009</year>, <volume>39</volume>, <fpage>427</fpage>&#8211;<lpage>448</lpage>.<pub-id pub-id-type="pmid">19514915</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10408440802412309</pub-id></mixed-citation></ref><ref id="R61"><label>(61)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Krippendorff</surname><given-names>B.-F.</given-names></name>; <name name-style="western"><surname>Neuhaus</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Lienau</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Reichel</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Huisinga</surname><given-names>W.</given-names></name><article-title>Mechanism-Based Inhibition: Deriving KI and Kinact Directly From Time-Dependent IC50 Values</article-title>. <source>SLAS Discovery</source><year>2009</year>, <volume>14</volume>, <fpage>913</fpage>&#8211;<lpage>923</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1087057109336751</pub-id><pub-id pub-id-type="pmid">19675314</pub-id></mixed-citation></ref><ref id="R62"><label>(62)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sliwoski</surname><given-names>G.</given-names></name>; <name name-style="western"><surname>Kothiwale</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Meiler</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Lowe</surname><given-names>E. W.</given-names></name><article-title>Computational Methods in Drug Discovery</article-title>. <source>Pharmacological Reviews</source><year>2014</year>, <volume>66</volume>, <fpage>334</fpage>&#8211;<lpage>395</lpage>.<pub-id pub-id-type="pmid">24381236</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/pr.112.007336</pub-id><pub-id pub-id-type="pmcid">PMC3880464</pub-id></mixed-citation></ref><ref id="R63"><label>(63)</label><mixed-citation publication-type="other"><name name-style="western"><surname>Kuzmi&#269;</surname><given-names>P.</given-names></name><source>Determination of Kinact and Ki for Covalent Inhibition Using the Omnia&#169;R Assay</source>; BioKin Technical Note TN-2015&#8211;02, <year>2015</year>.</mixed-citation></ref><ref id="R64"><label>(64)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kuzmi&#269;</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Solowiej</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Murray</surname><given-names>B. W.</given-names></name><article-title>An Algebraic Model for the Kinetics of Covalent Enzyme Inhibition at Low Substrate Concentrations</article-title>. <source>Analytical Biochemistry</source><year>2015</year>, <volume>484</volume>, <fpage>82</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="pmid">25433146</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ab.2014.11.014</pub-id></mixed-citation></ref><ref id="R65"><label>(65)</label><mixed-citation publication-type="other"><name name-style="western"><surname>Kuzmi&#269;</surname><given-names>P.</given-names></name><source>A Steady-State Algebraic Model for the Time Course of Covalent Enzyme Inhibition</source>. <year>2020</year>; ChemRxiv:chemrxiv.12445394.v3.</mixed-citation></ref><ref id="R66"><label>(66)</label><mixed-citation publication-type="other"><name name-style="western"><surname>Kuzmi&#269;</surname><given-names>P.</given-names></name><source>A Two-Point IC50 Method for Evaluating the Biochemical Potency of Irreversible Enzyme Inhibitors</source>. <year>2022</year>; bioRxiv:2020.06.25.171207.</mixed-citation></ref><ref id="R67"><label>(67)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ahmad</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Rizzi</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Capelli</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Mandelli</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Lyu</surname><given-names>W.</given-names></name>; <name name-style="western"><surname>Carloni</surname><given-names>P.</given-names></name><article-title>Enhanced-Sampling Simulations for the Estimation of Ligand Binding Kinetics: Current Status and Perspective</article-title>. <source>Frontiers in Molecular Biosciences</source><year>2022</year>, <volume>9</volume>, <fpage>899805</fpage>.<pub-id pub-id-type="pmid">35755817</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmolb.2022.899805</pub-id><pub-id pub-id-type="pmcid">PMC9216551</pub-id></mixed-citation></ref><ref id="R68"><label>(68)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mader</surname><given-names>L. K.</given-names></name>; <name name-style="western"><surname>Keillor</surname><given-names>J. W.</given-names></name><article-title>Fitting of Kinact and KI Values from Endpoint Pre-incubation IC50 Data</article-title>. <source>ACS Medicinal Chemistry Letters</source><year>2024</year>, <volume>15</volume>, <fpage>731</fpage>&#8211;<lpage>738</lpage>.<pub-id pub-id-type="pmid">38746886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acsmedchemlett.4c00054</pub-id><pub-id pub-id-type="pmcid">PMC11089659</pub-id></mixed-citation></ref><ref id="R69"><label>(69)</label><mixed-citation publication-type="book"><name name-style="western"><surname>Copeland</surname><given-names>R. A.</given-names></name><source>Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists</source>, <edition>1st ed</edition>.; <publisher-name>Wiley</publisher-name>, <year>2013</year>.<pub-id pub-id-type="pmid">16350889</pub-id></mixed-citation></ref><ref id="R70"><label>(70)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Srinivasan</surname><given-names>B.</given-names></name><article-title>A Guide to Enzyme Kinetics in Early Drug Discovery</article-title>. <source>The FEBS Journal</source><year>2023</year>, <volume>290</volume>, <fpage>2292</fpage>&#8211;<lpage>2305</lpage>.<pub-id pub-id-type="pmid">35175693</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/febs.16404</pub-id></mixed-citation></ref><ref id="R71"><label>(71)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Virtanen</surname><given-names>P.</given-names></name><etal/><article-title>SciPy 1.0: Fundamental Algorithms for Scientific Computing in Python</article-title>. <source>Nature Methods</source><year>2020</year>, <volume>17</volume>, <fpage>261</fpage>&#8211;<lpage>272</lpage>.<pub-id pub-id-type="pmid">32015543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41592-019-0686-2</pub-id><pub-id pub-id-type="pmcid">PMC7056644</pub-id></mixed-citation></ref><ref id="R72"><label>(72)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hindmarsh</surname><given-names>A. C.</given-names></name><article-title>ODEPACK, a Systematized Collection of ODE Solvers</article-title>. <source>Scientific Computing. Amsterdam</source>, <year>1983</year>; pp <fpage>55</fpage>&#8211;<lpage>64</lpage>.</mixed-citation></ref><ref id="R73"><label>(73)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Petzold</surname><given-names>L.</given-names></name><article-title>Automatic Selection of Methods for Solving Stiff and Nonstiff Systems of Ordinary Differential Equations</article-title>. <source>SIAM Journal on Scientific and Statistical Computing</source><year>1983</year>, <volume>4</volume>, <fpage>136</fpage>&#8211;<lpage>148</lpage>.</mixed-citation></ref><ref id="R74"><label>(74)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cornish-Bowden</surname><given-names>A.</given-names></name><article-title>Validity of a &#8216;Steady-State&#8217; Treatment of Inactivation Kinetics</article-title>. <source>Eur J Biochem</source><year>1979</year>, <volume>93</volume>, <fpage>383</fpage>&#8211;<lpage>385</lpage>.<pub-id pub-id-type="pmid">428388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1432-1033.1979.tb12834.x</pub-id></mixed-citation></ref><ref id="R75"><label>(75)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Michaelis</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Menten</surname><given-names>M. L.</given-names></name><article-title>Die kinetik der invertinwirkung</article-title>. <source>Biochem. z</source><year>1913</year>, <volume>49</volume>, <fpage>352</fpage>.</mixed-citation></ref><ref id="R76"><label>(76)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Briggs</surname><given-names>G. E.</given-names></name>; <name name-style="western"><surname>Haldane</surname><given-names>J. B. S.</given-names></name><article-title>A Note on the Kinetics of Enzyme Action</article-title>. <source>Biochemical Journal</source><year>1925</year>, <volume>19</volume>, <fpage>338</fpage>&#8211;<lpage>339</lpage>.<pub-id pub-id-type="pmid">16743508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/bj0190338</pub-id><pub-id pub-id-type="pmcid">PMC1259181</pub-id></mixed-citation></ref><ref id="R77"><label>(77)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Strelow</surname><given-names>J. M.</given-names></name><article-title>A Perspective on the Kinetics of Covalent and Irreversible Inhibition</article-title>. <source>SLAS Discovery: Advancing Life Sciences R&amp;D</source><year>2017</year>, <volume>22</volume>, <fpage>3</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">27703080</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1087057116671509</pub-id></mixed-citation></ref><ref id="R78"><label>(78)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hill</surname><given-names>A. V.</given-names></name><article-title>A New Mathematical Treatment of Changes of Ionic Concentration in Muscle and Nerve under the Action of Electric Currents, with a Theory as to Their Mode of Excitation</article-title>. <source>The Journal of Physiology</source><year>1910</year>, <volume>40</volume>, <fpage>190</fpage>&#8211;<lpage>224</lpage>.<pub-id pub-id-type="pmid">16993004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1113/jphysiol.1910.sp001366</pub-id><pub-id pub-id-type="pmcid">PMC1533746</pub-id></mixed-citation></ref><ref id="R79"><label>(79)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Arafet</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Scalvini</surname><given-names>L.</given-names></name>; <name name-style="western"><surname>Galvani</surname><given-names>F.</given-names></name>; <name name-style="western"><surname>Mart&#237;</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Moliner</surname><given-names>V.</given-names></name>; <name name-style="western"><surname>Mor</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Lodola</surname><given-names>A.</given-names></name><article-title>Mechanistic Modeling of Lys745 Sulfonylation in EGFR C797S Reveals Chemical Determinants for Inhibitor Activity and Discriminates Reversible from Irreversible Agents</article-title>. <source>Journal of Chemical Information and Modeling</source><year>2023</year>, <volume>63</volume>, <fpage>1301</fpage>&#8211;<lpage>1312</lpage>.<pub-id pub-id-type="pmid">36762429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.jcim.2c01586</pub-id><pub-id pub-id-type="pmcid">PMC9976278</pub-id></mixed-citation></ref><ref id="R80"><label>(80)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cornish-Bowden</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Koshland</surname><given-names>D. E.</given-names><suffix>Jr</suffix></name><article-title>Diagnostic Uses of the Hill (Logit and Nernst) Plots</article-title>. <source>Journal of Molecular Biology</source><year>1975</year>, <volume>95</volume>, <fpage>201</fpage>&#8211;<lpage>212</lpage>.<pub-id pub-id-type="pmid">171413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0022-2836(75)90390-3</pub-id></mixed-citation></ref><ref id="R81"><label>(81)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Buchler</surname><given-names>N. E.</given-names></name>; <name name-style="western"><surname>Louis</surname><given-names>M.</given-names></name><article-title>Molecular Titration and Ultrasensitivity in Regulatory Networks</article-title>. <source>Journal of Molecular Biology</source><year>2008</year>, <volume>384</volume>, <fpage>1106</fpage>&#8211;<lpage>1119</lpage>.<pub-id pub-id-type="pmid">18938177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmb.2008.09.079</pub-id></mixed-citation></ref><ref id="R82"><label>(82)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Schwartz</surname><given-names>P. A.</given-names></name>; <name name-style="western"><surname>Kuzmic</surname><given-names>P.</given-names></name>; <name name-style="western"><surname>Solowiej</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Bergqvist</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Bolanos</surname><given-names>B.</given-names></name>; <name name-style="western"><surname>Almaden</surname><given-names>C.</given-names></name>; <name name-style="western"><surname>Nagata</surname><given-names>A.</given-names></name>; <name name-style="western"><surname>Ryan</surname><given-names>K.</given-names></name>; <name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name>; <name name-style="western"><surname>Dalvie</surname><given-names>D.</given-names></name>; <name name-style="western"><surname>Kath</surname><given-names>J. C.</given-names></name>; <name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Wani</surname><given-names>R.</given-names></name>; <name name-style="western"><surname>Murray</surname><given-names>B. W.</given-names></name><article-title>Covalent EGFR Inhibitor Analysis Reveals Importance of Reversible Interactions to Potency and Mechanisms of Drug Resistance</article-title>. <source>Proc. Natl. Acad. Sci. U.S.A.</source><year>2014</year>, <volume>111</volume>, <fpage>173</fpage>&#8211;<lpage>178</lpage>.<pub-id pub-id-type="pmid">24347635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1313733111</pub-id><pub-id pub-id-type="pmcid">PMC3890870</pub-id></mixed-citation></ref><ref id="R83"><label>(83)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bradshaw</surname><given-names>J. M.</given-names></name><etal/><article-title>Prolonged and Tunable Residence Time Using Reversible Covalent Kinase Inhibitors</article-title>. <source>Nat. Chem. Biol.</source><year>2015</year>, <volume>11</volume>, <fpage>525</fpage>&#8211;<lpage>531</lpage>.<pub-id pub-id-type="pmid">26006010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nchembio.1817</pub-id><pub-id pub-id-type="pmcid">PMC4472506</pub-id></mixed-citation></ref><ref id="R84"><label>(84)</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhao</surname><given-names>M.</given-names></name>; <name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name>; <name name-style="western"><surname>Vivona</surname><given-names>S.</given-names></name>; <name name-style="western"><surname>Cipriano</surname><given-names>D. J.</given-names></name>; <name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name>; <name name-style="western"><surname>Brunger</surname><given-names>A. T.</given-names></name><article-title>Mechanistic Insights Into the Recycling Machine of the SNARE Complex</article-title>. <source>Nature</source><year>2015</year>,<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature14148</pub-id><pub-id pub-id-type="pmcid">PMC4320033</pub-id><pub-id pub-id-type="pmid">25581794</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1:</label><caption><p id="P33">Simulated time courses of the total occupancy from <xref rid="FD2" ref-type="disp-formula">Scheme 2</xref> (bottom) and its noncovalent version from <xref rid="FD8" ref-type="disp-formula">Scheme 4</xref> (top) for different values of <inline-formula><mml:math id="M2" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> with <inline-formula><mml:math id="M3" display="inline"><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mspace width="0.5em"/><mml:mtext>nM</mml:mtext></mml:math></inline-formula>, <inline-formula><mml:math id="M4" display="inline"><mml:mo>[</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mi>&#956;</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:math></inline-formula>, <inline-formula><mml:math id="M5" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>&#956;</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>, <inline-formula><mml:math id="M6" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>, and <inline-formula><mml:math id="M7" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>. The occupancy of a one-step scheme is also included (black-dashed) to illustrate the contribution of binding affinity, <inline-formula><mml:math id="M8" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2025.05.28.656658v1-f0002.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2:</label><caption><p id="P34">Noncovalent residence time <inline-formula><mml:math id="M9" display="inline"><mml:mo>(</mml:mo><mml:mi>&#964;</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> of a bound ligand as a function of <inline-formula><mml:math id="M10" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M11" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mspace width="0.5em"/><mml:mtext>nM</mml:mtext></mml:math></inline-formula>, <inline-formula><mml:math id="M12" display="inline"><mml:mo>[</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mi>&#956;</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:math></inline-formula>, and <inline-formula><mml:math id="M13" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>&#956;</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>. The residence times calculated analytically from <xref rid="FD12" ref-type="disp-formula">eq 8</xref> or numerically from simulations of <xref rid="FD8" ref-type="disp-formula">Scheme 4</xref> are the same.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2025.05.28.656658v1-f0003.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3:</label><caption><p id="P35">Simulated time-responses of covalent occupancy <inline-formula><mml:math id="M14" display="inline"><mml:mo>(</mml:mo><mml:mo>[</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mspace width="0.5em"/><mml:mi>&#956;</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mo>)</mml:mo></mml:math></inline-formula> (top) and dose-rate (bottom) data for different values of <inline-formula><mml:math id="M15" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> with <inline-formula><mml:math id="M16" display="inline"><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mspace width="0.5em"/><mml:mtext>nM</mml:mtext></mml:math></inline-formula>, <inline-formula><mml:math id="M17" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>&#956;</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>, <inline-formula><mml:math id="M18" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>, and <inline-formula><mml:math id="M19" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>. The ODEs of <xref rid="FD7" ref-type="disp-formula">Scheme 3</xref> were solved numerically for the time-responses (top), and the fraction of the covalent complex was fit for <inline-formula><mml:math id="M20" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>obs</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> with <xref rid="FD14" ref-type="disp-formula">eq 9</xref> (bottom).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2025.05.28.656658v1-f0004.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Figure 4:</label><caption><p id="P36">Comparisons between <xref rid="FD21" ref-type="disp-formula">eq 16</xref> (darkened dashed line) and ODE-based numerical simulations of <xref rid="FD7" ref-type="disp-formula">Scheme 3</xref> (solid line) for three representative cases. In Case 2, the parameters are <inline-formula><mml:math id="M21" display="inline"><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mtext>DR</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>7.1</mml:mn><mml:mspace width="0.5em"/><mml:mi mathvariant="normal">h</mml:mi></mml:math></inline-formula>, <inline-formula><mml:math id="M22" display="inline"><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mspace width="0.5em"/><mml:mtext>nM</mml:mtext></mml:math></inline-formula>, <inline-formula><mml:math id="M23" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>&#956;</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>, <inline-formula><mml:math id="M24" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>5</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>, and <inline-formula><mml:math id="M25" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>5</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>. The altered parameters for Case 1 are <inline-formula><mml:math id="M26" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>5</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup><mml:mi>&#956;</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula> and <inline-formula><mml:math id="M27" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>5</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>. The altered parameters for Case 3 are <inline-formula><mml:math id="M28" display="inline"><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mi>&#956;</mml:mi><mml:mi mathvariant="normal">M</mml:mi></mml:math></inline-formula>, <inline-formula><mml:math id="M29" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>5</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup><mml:mi>&#956;</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>, and <inline-formula><mml:math id="M30" display="inline"><mml:msubsup><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow><mml:mrow><mml:mtext>app</mml:mtext></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>5</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>3</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>. The fitted values of <inline-formula><mml:math id="M31" display="inline"><mml:mi>n</mml:mi></mml:math></inline-formula> for cases 1, 2, and 3 are 1.47, 1.03, and 1.11, respectively.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2025.05.28.656658v1-f0005.jpg"/></fig><fig position="float" id="F5" orientation="portrait"><label>Figure 5:</label><caption><p id="P37">The variation of dose-response data (simulated by numerically solving the ODEs of <xref rid="FD7" ref-type="disp-formula">Scheme 3</xref>) as a function of <inline-formula><mml:math id="M32" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> (left column), <inline-formula><mml:math id="M33" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> (middle column), and <inline-formula><mml:math id="M34" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> (right column) when <inline-formula><mml:math id="M35" display="inline"><mml:msub><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mtext>DR</mml:mtext></mml:mrow></mml:msub></mml:math></inline-formula> is 0.7 (top row), 7.1 (middle row), and 71.1 (bottom row) hours. The default parameters are <inline-formula><mml:math id="M36" display="inline"><mml:mo>[</mml:mo><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mspace width="0.5em"/><mml:mtext>nM</mml:mtext></mml:math></inline-formula>, <inline-formula><mml:math id="M37" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>&#956;</mml:mi><mml:msup><mml:mrow><mml:mi mathvariant="normal">M</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>, <inline-formula><mml:math id="M38" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>, <inline-formula><mml:math id="M39" display="inline"><mml:msub><mml:mrow><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mtext>inact</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#215;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="normal">s</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>, and <inline-formula><mml:math id="M40" display="inline"><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.5</mml:mn></mml:math></inline-formula>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2025.05.28.656658v1-f0006.jpg"/></fig></floats-group></article></pmc-articleset>